Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) CAO Sells $11,160.60 in Stock

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Get Rating) CAO Theodore Alan Huizenga sold 132 shares of the business’s stock in a transaction dated Saturday, April 16th. The stock was sold at an average price of $84.55, for a total transaction of $11,160.60. Following the completion of the sale, the chief accounting officer now directly owns 16,914 shares of the company’s stock, valued at approximately $1,430,078.70. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

RARE stock traded up $1.17 on Tuesday, hitting $79.61. 3,980 shares of the company’s stock traded hands, compared to its average volume of 437,963. Ultragenyx Pharmaceutical Inc. has a 1-year low of $61.21 and a 1-year high of $119.54. The firm has a market cap of $5.52 billion, a PE ratio of -11.69 and a beta of 1.68. The stock’s fifty day moving average is $71.42.

Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Rating) last issued its quarterly earnings results on Thursday, February 10th. The biopharmaceutical company reported ($1.79) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.32) by ($0.47). The firm had revenue of $83.39 million during the quarter, compared to analysts’ expectations of $83.68 million. Ultragenyx Pharmaceutical had a negative net margin of 129.20% and a negative return on equity of 44.24%. The firm’s revenue was down 8.9% compared to the same quarter last year. During the same quarter last year, the company posted ($1.34) EPS. Equities analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -6.57 earnings per share for the current fiscal year.

Several large investors have recently modified their holdings of RARE. Benjamin F. Edwards & Company Inc. purchased a new stake in shares of Ultragenyx Pharmaceutical in the 3rd quarter valued at approximately $66,000. Alpha Paradigm Partners LLC acquired a new position in Ultragenyx Pharmaceutical in the 4th quarter valued at approximately $113,000. Advisor Group Holdings Inc. increased its stake in Ultragenyx Pharmaceutical by 26.6% in the 3rd quarter. Advisor Group Holdings Inc. now owns 1,612 shares of the biopharmaceutical company’s stock valued at $146,000 after buying an additional 339 shares during the period. Trek Financial LLC acquired a new position in Ultragenyx Pharmaceutical in the 4th quarter valued at approximately $205,000. Finally, Allspring Global Investments Holdings LLC acquired a new position in shares of Ultragenyx Pharmaceutical during the 4th quarter worth $207,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

RARE has been the subject of a number of recent research reports. StockNews.com initiated coverage on shares of Ultragenyx Pharmaceutical in a research report on Thursday, March 31st. They set a “hold” rating for the company. JPMorgan Chase & Co. upgraded shares of Ultragenyx Pharmaceutical from a “neutral” rating to an “overweight” rating and set a $132.00 target price for the company in a research report on Friday, February 11th. Zacks Investment Research upgraded shares of Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating and set a $75.00 target price for the company in a research report on Tuesday, February 15th. Morgan Stanley decreased their target price on shares of Ultragenyx Pharmaceutical from $120.00 to $118.00 and set an “overweight” rating for the company in a research report on Friday, February 11th. Finally, Credit Suisse Group upgraded shares of Ultragenyx Pharmaceutical from a “neutral” rating to an “outperform” rating and upped their target price for the stock from $99.00 to $105.00 in a research report on Wednesday, March 16th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and ten have given a buy rating to the company. According to data from MarketBeat.com, Ultragenyx Pharmaceutical currently has an average rating of “Buy” and a consensus target price of $122.27.

Ultragenyx Pharmaceutical Company Profile (Get Rating)

Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. Mepsevii is an intravenous, which is used for the treatment of Mucopolysaccharidosis VII.

Featured Articles